Navigation Links
Harwood Feffer LLP Announces Investigation of Santarus, Inc.
Date:11/8/2013

NEW YORK, Nov. 8, 2013 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Santarus, Inc. ("Santarus" or the "Company") (NASDAQ: SNTS) concerning the proposed acquisition of the Company by Salix Pharmaceuticals, Ltd. ("Salix").    

(Logo: http://photos.prnewswire.com/prnh/20120215/MM54604LOGO )

On November 8, 2013, Santarus announced that it had entered into a definitive agreement pursuant to which the Company will be acquired by Salix.  Under the terms of the agreement, Santarus shareholders will receive $32.00 per Santarus share in cash.    

Our investigation concerns whether the Santarus board of directors is fulfilling its fiduciary duties, maximizing the value of the Company, disclosing all material benefits and costs, and obtaining full and fair consideration for Company shareholders. 

If you own Santarus shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:

Benjamin I. Sachs-Michaels, Esq.
Robert I. Harwood, Esq.
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
(212)935-7400
Email: bsachsmichaels@hfesq.com
Website: http://www.hfesq.com

Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.

Attorney Advertising © 2013 Harwood Feffer LLP. The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.


'/>"/>
SOURCE Harwood Feffer LLP
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Harwood Feffer LLP Announces Investigation of Transcept Pharmaceuticals, Inc.
2. Updated: Harwood Feffer LLP Announces Investigation of Edwards Lifesciences Corporation
3. Harwood Feffer LLP Announces Investigation of OvaScience, Inc.
4. Harwood Feffer LLP Announces Investigation of Spectrum Pharmaceuticals, Inc.
5. Harwood Feffer LLP Announces Investigation of MAP Pharmaceuticals, Inc.
6. Harwood Feffer LLP Announces Investigation of DUSA Pharmaceuticals, Inc.
7. Harwood Feffer LLP Announces Investigation of PSS World Medical, Inc.
8. Harwood Feffer LLP Announces Investigation of Questcor Pharmaceuticals, Inc.
9. Stason Pharmaceuticals Inc. announces Kansas City expansion, adds human health capabilities
10. Imprimis Pharmaceuticals, Inc. Announces Its Attendance at the American Academy of Ophthalmology in New Orleans, Nov. 16-19
11. IceCure Medical Ltd. announces treatment of first breast cancer patient using its IceSense3 Cryoablation System at John Wayne Cancer Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , May 25, 2016 ... the precision of circulating tumour DNA (ctDNA) analysis ... the appointment of Professor Clive Morris ... leadership across the clinical development programme, scientific collaborations, ... help deliver significant improvements in clinical outcomes for ...
(Date:5/24/2016)... , May 24, 2016 ... Markt gebracht, die es Ärzten erlaubt, ihre Expertise ... behandeln: MDLinking kombiniert Live Streaming mit einer Instant-Messaging-Funktion ... zu kommunizieren. Mediziner in Europa, Afrika, Asien und ... bereits für die Plattform registriert. Information ...
(Date:5/24/2016)... , May 24, 2016 ... beide primären Endpunkte und demonstriert ... in ‚ausgezeichneter plus guter , ...    ,      (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ... heute neue positive Daten von der MORA-Studie der ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... May 25, 2016 , ... ... seen a significant spike in their clients' employee participation for their wellness initiatives. ... screening by implementing a high-deductible health plan with outcome-based deductible incentives. As a ...
(Date:5/25/2016)... Jersey (PRWEB) , ... May 25, 2016 , ... ... technology firm will be selling the device branded as Stern’s Real Time Monitoring ... geared to bedbugs to the hotel and motel industry, colleges for use in dormitories, ...
(Date:5/24/2016)... ... May 24, 2016 , ... PhishLine, the best-in-class, enterprise ... company as Vice President of Sales. Cifolelli’s primary responsibilities include management of ... the rapidly expanding field of organizational social engineering. , “We are delighted ...
(Date:5/24/2016)... ... ... Jericho Project has named LaToya Williams-Belfort to the position of Chief Development and Communications ... the nationally-acclaimed nonprofit, working closely with CEO Tori Lyon and the Board of Directors ... , “LaToya Williams-Belfort is joining Jericho at an exciting time of growth and ...
(Date:5/24/2016)... , ... May 24, 2016 , ... How to Write ... Raleigh, NC, http://www.fdanews.com/humanerrordrugdevice , Human error is known to be the major ... human error will ever be totally eliminated, many human performance problems can be prevented. ...
Breaking Medicine News(10 mins):